Author

Z. C. Nwosu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:statistical model· 4 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Assay:metabolomics· 2 Organism:mouse· 2

Frequent Co-Authors

C. A. Lyssiotis· 5 shared C. J. Halbrook· 4 shared M. Pasca di Magliano· 3 shared R. E. Menjivar· 3 shared A. Andren· 2 shared B. S. Nelson· 2 shared H. C. Crawford· 2 shared J. Ramos· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

C. A. Lyssiotis

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Arginase 1 is a key driver of immune suppression in pancreatic cancer

R. E. Menjivar, Z. C. Nwosu, W. Du, K. Donahue, C. Espinoza, K. Brown, A. Velez, W. Yan, F. Lima, A. Bischoff, P. Kadiyala, D. Salas-Escabillas, C. J. Halbrook, F. Bednar, E. Carpenter, , M. di Magliano

This study shows that Arginase 1 suppresses immune responses in pancreatic cancer by inhibiting T cell activation, and targeting it enhances immunotherapy effectiveness.

bioRxiv · Jun 21, 2022Cancer Biology

Nutrient profiling reveals extracellular uridine as a fuel for pancreatic cancer through uridine phosphorylase 1

M. H. Ward, Z. C. Nwosu, P. Poudel, S. Kasperek, Z. Tolstyka, R. E. Menjivar, C. Ragulan, G. Nyamundanda, L. Zhang, A. Andren, C. J. Halbrook, E. S. Carpenter, M. Pasca di Magliano, A. Sadanandam, C. A. Lyssiotis

This study identifies uridine as a novel nutrient for pancreatic cancer cells through uridine phosphorylase 1, showing its role in survival and metabolism under glucose deprivation.

bioRxiv · Jun 7, 2021 · PreprintCancer Biology

Multi-dimensional analyses identify genes of high priority for pancreatic cancer research

Z. C. Nwosu, H. Giza, M. Nassif, V. Charlestin, R. E. Menjivar, D. Kim, S. Kemp, N. Steele, J. Hu, B. Hu, S. Wang, M. Pasca di Magliano, C. A. Lyssiotis

The paper identifies consistently expressed genes in pancreatic ductal adenocarcinoma (PDAC) to prioritize therapeutic targets and biomarkers.

bioRxiv · May 28, 2021 · PreprintCancer Biology

The Pancreatic Tumor Microenvironment Compensates for Loss of GOT2

S. A. Kerk, L. Lin, A. L. Myers, Y. Zhang, J. A. Jimenez, P. Sajjakulnukit, B. S. Nelson, B. Chen, A. Robinson, G. Thurston, S. B. Kemp, N. G. Steele, M. T. Hoffman, H.-J. Wen, D. Long, , C. A. Lyssiotis

This study shows that the pancreatic tumor microenvironment compensates for loss of GOT2 by providing pyruvate, maintaining redox homeostasis and tumor growth in vivo.

bioRxiv · Aug 7, 2020Cancer Biology

Tissue of Origin Dictates GOT1 Dependence and Confers Synthetic Lethality to Radiotherapy

B. S. Nelson, L. Lin, D. M. Kremer, C. M. Sousa, C. Cotta-Ramusino, A. Myers, J. Ramos, T. Gao, I. Kovalenko, K. Wilder-Romans, J. Dresser, M. Davis, H.-J. Lee, Z. C. Nwosu, S. Campit, , C. A. Lyssiotis

The paper shows that pancreatic ductal adenocarcinoma (PDA) is more dependent on GOT1 than colorectal cancer (CRC) and that GOT1 inhibition synergizes with radiotherapy to inhibit PDA growth.

Cancer & Metabolism · Jan 2, 2020Peer-reviewedCancer Biology